Sudevan ST - Search Results

1

Review of β-carboline and its derivatives as selective MAO-A inhibitors.

Benny F, Kumar S, Jayan J, Abdelgawad MA, Ghoneim MM, Kumar A, Manoharan A, Susan R, Sudevan ST, Mathew B. Benny F, et al. Among authors: sudevan st. Arch Pharm (Weinheim). 2023 Jul;356(7):e2300091. doi: 10.1002/ardp.202300091. Epub 2023 Apr 6. Arch Pharm (Weinheim). 2023. PMID: 37021551 Review.

2

Development of Halogenated Pyrazolines as Selective Monoamine Oxidase-B Inhibitors: Deciphering via Molecular Dynamics Approach.

Nair AS, Oh JM, Koyiparambath VP, Kumar S, Sudevan ST, Soremekun O, Soliman ME, Khames A, Abdelgawad MA, Pappachen LK, Mathew B, Kim H. Nair AS, et al. Among authors: sudevan st. Molecules. 2021 May 28;26(11):3264. doi: 10.3390/molecules26113264. Molecules. 2021. PMID: 34071665 Free PMC article.

3

Deciphering the detailed structure-activity relationship of coumarins as Monoamine oxidase enzyme inhibitors-An updated review.

Koyiparambath VP, Prayaga Rajappan K, Rangarajan TM, Al-Sehemi AG, Pannipara M, Bhaskar V, Nair AS, Sudevan ST, Kumar S, Mathew B. Koyiparambath VP, et al. Among authors: sudevan st. Chem Biol Drug Des. 2021 Oct;98(4):655-673. doi: 10.1111/cbdd.13919. Epub 2021 Jul 26. Chem Biol Drug Des. 2021. PMID: 34233082 Review.

4

Navigating into the Chemical Space of Monoamine Oxidase Inhibitors by Artificial Intelligence and Cheminformatics Approach.

Kumar S, Nair AS, Bhashkar V, Sudevan ST, Koyiparambath VP, Khames A, Abdelgawad MA, Mathew B. Kumar S, et al. Among authors: sudevan st. ACS Omega. 2021 Sep 1;6(36):23399-23411. doi: 10.1021/acsomega.1c03250. eCollection 2021 Sep 14. ACS Omega. 2021. PMID: 34549139 Free PMC article.

5

Conjugated Dienones from Differently Substituted Cinnamaldehyde as Highly Potent Monoamine Oxidase-B Inhibitors: Synthesis, Biochemistry, and Computational Chemistry.

Mathew B, Oh JM, Abdelgawad MA, Khames A, Ghoneim MM, Kumar S, Nath LR, Sudevan ST, Parambi DGT, Agoni C, Soliman MES, Kim H. Mathew B, et al. Among authors: sudevan st. ACS Omega. 2022 Feb 24;7(9):8184-8197. doi: 10.1021/acsomega.2c00397. eCollection 2022 Mar 8. ACS Omega. 2022. PMID: 35284720 Free PMC article.

6

A Review on Benzimidazole Scaffolds as Inhibitors of Mycobacterium tuberculosis Mycolyl-arabinogalactan-peptidoglycan Complex Biosynthesis.

Bhaskar V, Kumar S, Nair AS, Rajappan KP, Sudevan ST, Parambi DGT, Al-Sehemi AG, Zachariah SM, Pappachen LK. Bhaskar V, et al. Among authors: sudevan st. Comb Chem High Throughput Screen. 2023;26(4):668-681. doi: 10.2174/1386207325666220415144511. Comb Chem High Throughput Screen. 2023. PMID: 35430964 Review.

7

Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidase-B inhibitors.

Sudevan ST, Rangarajan TM, Al-Sehemi AG, Nair AS, Koyiparambath VP, Mathew B. Sudevan ST, et al. Arch Pharm (Weinheim). 2022 Aug;355(8):e2200084. doi: 10.1002/ardp.202200084. Epub 2022 May 13. Arch Pharm (Weinheim). 2022. PMID: 35567313 Review.

8

Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors.

Sudevan ST, Oh JM, Abdelgawad MA, Abourehab MAS, Rangarajan TM, Kumar S, Ahmad I, Patel H, Kim H, Mathew B. Sudevan ST, et al. Sci Rep. 2022 Dec 27;12(1):22404. doi: 10.1038/s41598-022-26929-x. Sci Rep. 2022. PMID: 36575270 Free PMC article.

9

Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer's Disease.

Kumar A, Sudevan ST, Nair AS, Singh AK, Kumar S, Jose J, Behl T, Mangalathillam S, Mathew B, Kim H. Kumar A, et al. Among authors: sudevan st. Brain Sci. 2023 Jan 27;13(2):213. doi: 10.3390/brainsci13020213. Brain Sci. 2023. PMID: 36831756 Free PMC article. Review.

10

Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders.

Srivastava P, Sudevan ST, Thennavan A, Mathew B, Kanthlal SK. Srivastava P, et al. Among authors: sudevan st. CNS Neurol Disord Drug Targets. 2024;23(3):331-341. doi: 10.2174/1871527322666230303115236. CNS Neurol Disord Drug Targets. 2024. PMID: 36872357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page